PDS Biotech Appoints Three Pharma Executives to Board
PDS Biotechnology has appointed John Dawson, Deborah Ramsdell, and Bruce Wendel to its board as it advances PDS0301 toward a Phase 3 trial in metastatic colorectal cancer. The move aims to bolster corporate development and partnership strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed